Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Protocol: Benefits and harms of remdesivir for COVID-19 in adults: A systematic review with meta-analysis

Research output: Contribution to journalReviewResearchpeer-review

  1. "We can't do without it": Parent and call-handler experiences of video triage of children at a medical helpline

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: A randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: A nationwide study and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

    Research output: Contribution to journalLetterResearchpeer-review

  3. Intimate Partner Violence and Electronic Health Interventions: Systematic Review and Meta-Analysis of Randomized Trials

    Research output: Contribution to journalReviewResearchpeer-review

  • Asger Sand Paludan-Müller
  • Andreas Lundh
  • Matthew J Page
  • Klaus Munkholm
View graph of relations

BACKGROUND: Effective drug treatments for Covid-19 are needed to decrease morbidity and mortality for the individual and to alleviate pressure on health care systems. Remdesivir showed promising results in early randomised trials but subsequently a large publicly funded trial has shown less favourable results and the evidence is interpreted differently in clinical guidelines. Systematic reviews of remdesivir have been published, but none have systematically searched for unpublished data, including regulatory documents, and assessed the risk of bias due to missing evidence.

METHODS: We will conduct a systematic review of randomised trials comparing remdesivir to placebo or standard of care in any setting. We will include trials regardless of the severity of disease and we will include trials examining remdesivir for indications other than Covid-19 for harms analyses. We will search websites of regulatory agencies, trial registries, bibliographic databases, preprint servers and contact trial sponsors to obtain all available data, including unpublished clinical data, for all eligible trials. Our primary outcomes will be all-cause mortality and serious adverse events. Our secondary outcomes will be length of hospital stay, time to death, severe disease, and adverse events. We will assess the risk of bias using the Cochranes Risk of Bias 2 tool and the risk of bias due to missing evidence (e.g. publication bias, selective reporting bias) using the ROB-ME tool. Where appropriate we will synthesise study results by conducting random-effects meta-analysis. We will present our findings in a Summary of Findings table and rate the certainty of the evidence using the GRADE approach.

DISCUSSION: By conducting a comprehensive systematic review including unpublished data (where available), we expect to be able to provide valuable information for patients and clinicians about the benefits and harms of remdesivir for the treatment of Covid-19. This will help to ensure optimal treatment for individual patients and optimal utilisation of health care resources.

SYSTEMATIC REVIEW REGISTRATION: CRD42021255915.

Original languageEnglish
Article numbere0260544
JournalPLoS One
Volume16
Issue number11
Pages (from-to)1-13
Number of pages13
ISSN1932-6203
DOIs
Publication statusPublished - 29 Nov 2021

ID: 69544582